InNexus Biotechnology Inc. (TSX: IXS.V) (www.ixsbio.com), a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL™) technology, today announced the Company and the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH), have amended the Collaborative Agreement announced on May 27, 2010, involving research on technologies developed by InNexus.
“Under the amended agreement we will receive additional immunotoxins for modification in our own facilities to enhance activity and function and the NCI will evaluate the modified immunotoxins against unmodified product.”
"Under the existing collaborative agreement, the NCI will continue to evaluate our proprietary technology as applied to certain immunotoxins currently in development at the NCI," said Dr. Thomas Kindt, Chief Scientific Officer of InNexus. "Under the amended agreement we will receive additional immunotoxins for modification in our own facilities to enhance activity and function and the NCI will evaluate the modified immunotoxins against unmodified product."
Jeff Morhet, InNexus CEO, said, "Work will now be conducted in both houses, and our R&D effort is expanded. Our scientists are excited to apply InNexus technology to the NCI's anti-cancer compounds (immunotoxins) in our laboratories. These modified products will be tested by the NCI for activity against tumor cells in comparison with the unmodified compounds giving independent evaluation of our new technology."
A new era of targeted therapy with antibody–drug conjugates